Skip to main content

Advertisement

SpringerLink
Log in

The evaluation of the efficacy of adalimumab in refractory non-infectious uveitis with ultra-widefield fundus fluorescein angiography

  • Original Paper
  • Published:
International Ophthalmology Aims and scope Submit manuscript

Abstract

Aim

To investigate the efficacy of adalimumab in the cases with refractory non-infectious uveitis and evaluate retinal vascular leakage changes on ultra-widefield fundus fluorescein angiography.

Methods

Twenty-three patients with refractory uveitis were included in study.

Results

Forty-four eyes of 23 patients with non-infectious uveitiswere evaluated. Clinically active inflammation was present in 19 eyes (43.18%), while 25 (56.8%) were inactive. The mean drug burden was a 9.91 ± 3.78 (5–21) in baseline, 7.3 ± 4.25 at third and 8.0 ± 4.71 at sixth month (p = 0.022). The mean choroidal thickness was 256.65 ± 43.63 μm in baseline, 240.49 ± 36.73 μm at third and 224.81 ± 34.91 μm at sixth month (p ≤ 0.05). In terms of leakage extend, leakage was initially present in a mean of 2.95 ± 4.55 clock hours, 2.41 ± 3.91 at third and 1.76 ± 3.44 at sixth month (p < 0.001).

Conclusion

Adalimumab was found to be effective in establishing inflammation control by reducing drug burden, controlling retinal vascular leakage and choroidal inflammation in refractory uveitis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Gritz DC, Wong IG (2004) Incidence and prevalence of uveitis in Northern California; the Northern California Epidemiology of Uveitis Study. Ophthalmology 111(3):491–500

    Article  Google Scholar 

  2. Chang JH, Wakefield D (2002) Uveitis: a global perspective. Ocul Immunol Inflamm 10(4):263–279

    Article  Google Scholar 

  3. Diaz-Llopis M, García-Delpech S, Salom D et al (2008) Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 24(3):351–361

    Article  CAS  Google Scholar 

  4. Díaz-Llopis M, Salom D, Garcia-de-Vicuña C et al (2012) Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology 119(8):1575–1581

    Article  Google Scholar 

  5. Tugal-Tutkun I, Mudun A, Urgancioglu M et al (2005) Efficacy of infliximab in the treatment of uveitisthat is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum 52(8):2478–2484

    Article  CAS  Google Scholar 

  6. SantosLacomba M, MarcosMartín C, GallardoGalera JM et al (2001) Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res 33(5):251–255

    Article  CAS  Google Scholar 

  7. Lee JT, Yates WB, Rogers S et al (2018) Adalimumab for the treatment of refractory active and inactive non-infectious uveitis. Br J Ophthalmol 102(12):1672–1678

    Article  Google Scholar 

  8. Bawazeer A, Raffa LH, Nizamuddin SH (2010) Clinical experience with adalimumab in the treatment of ocular Behçet disease. Ocul Immunol Inflamm 18(3):226–232

    Article  CAS  Google Scholar 

  9. Jaffe GJ, Dick AD, Brézin AP et al (2016) Adalimumab in patients with active noninfectious uveitis. N Engl J Med 375(10):932–943

    Article  CAS  Google Scholar 

  10. Nguyen QD, Merrill PT, Jaffe GJ et al (2016) Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 388(10050):1183–1192

    Article  CAS  Google Scholar 

  11. Jabs DA, Nussenblatt RB, Rosenbaum JT (2005) Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509–516

    Article  Google Scholar 

  12. Nussenblatt RB, Palestine AG, Chan CC et al (1985) Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology 92(4):467–471

    Article  CAS  Google Scholar 

  13. Nussenblatt RB, Peterson JS, Foster CS et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series. Ophthalmology 112(5):764–770

    Article  Google Scholar 

  14. Busch M, Bauer D, Hennig M et al (2013) Effects of systemic and intravitreal TNF-α inhibition in experimental autoimmune uveo retinitis. Invest Ophthalmol Vis Sci 54(1):39–46

    Article  CAS  Google Scholar 

  15. Levy-Clarke G, Jabs DA, Read RW et al (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(3):785–96.e3

    Article  Google Scholar 

  16. Hasegawa E, Takeda A, Yawata N et al (2019) The effectiveness of adalimumab treatment for non-infectious uveitis. Immunol Med 42(2):79–83

    Article  Google Scholar 

  17. Martín-Varillas JL, Calvo-Río V, Beltrán E et al (2018) Successful optimization of adalimumab therapy in refractory uveitis due to Behçet’s disease. Ophthalmology 125(9):1444–1451

    Article  Google Scholar 

  18. Keino H, Okada AA, Watanabe T et al (2011) Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet’s disease on infliximab therapy. Br J Ophthalmol 95(9):1245–1250

    Article  Google Scholar 

  19. Mesquida M, Llorenç V, Fontenla JR et al (2014) Use of ultra-wide-field retinal imaging in the management of active Behçet retinal vasculitis. Retina 34(10):2121–2127

    Article  Google Scholar 

  20. Leder HA, Campbell JP, Sepah YJ et al (2013) Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. J Ophthalmic Inflamm Infect 3(1):30

    Article  Google Scholar 

  21. Pirani V, Pelliccioni P, De Turris S et al (2020) Intraocular inflammation control and changes in retinal and choroidal architecture in refractory non-infectious uveitis patients after adalimumab therapy. J Clin Med 9(2):510

    Article  CAS  Google Scholar 

  22. Fabiani C, Vitale A, Emmi G et al (2017) Efficacy and safety of adalimumab in Behçet’s disease-related uveitis: a multicenter retrospective observational study. Clin Rheumatol 36(1):183–189

    Article  Google Scholar 

  23. Fabiani C, Sota J, Rigante D et al (2018) Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clin Rheumatol 37(10):2805–2809

    Article  Google Scholar 

  24. Sharma PK, Markov GT, Bajwa A et al (2015) Long-term efficacy of systemic infliximab in recalcitrant retinal vasculitis. Retina 35(12):2641–2646

    Article  CAS  Google Scholar 

  25. Keino H, Okada AA, Watanabe T et al (2014) Long-termefficacy of infliximab on background vascular leakage in patients with Behçet’s disease. Eye (London) 28(9):1100–1106

    Article  CAS  Google Scholar 

  26. Vallet H, Riviere S, Sanna A et al (2015) Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease: multicenter study of 124 patients. J Autoimmun 62:67–74

    Article  CAS  Google Scholar 

  27. Durrani K, Kempen JH, Ying GS et al (2017) Adalimumab for ocular inflammation. Ocul Immunol Inflamm 25(3):405–412

    Article  CAS  Google Scholar 

  28. Kempen JH, Sugar EA, Jaffe GJ et al (2013) Fluorescein angiography versus optical coherence tomography for diagnosis of uveitic macular edema. Ophthalmology 120(9):1852–1859

    Article  Google Scholar 

  29. Ossewaarde-vanNorel J, Camfferman LP, Rothova A (2012) Discrepancies between fluorescein angiography and optical coherence tomography in macular edema in uveitis. Am J Ophthalmol 154(2):233–239

    Article  Google Scholar 

Download references

Funding

There is no funding support for this manuscuript.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, Medical Faculty, Karadeniz Technical University, Trabzon, Turkey

    Dilek Uzlu, Nurettin Akyol, Hidayet Erdöl & Murat Günay

  2. The State Hospital of Bayburt, Bayburt, Turkey

    Büşra Köse

Authors
  1. Dilek Uzlu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Büşra Köse
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nurettin Akyol
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hidayet Erdöl
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Murat Günay
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dilek Uzlu.

Ethics declarations

Conflict of interest

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study was approved by Karadeniz Technical University, Faculty of Medicine, Ethic Council on 2020/209.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uzlu, D., Köse, B., Akyol, N. et al. The evaluation of the efficacy of adalimumab in refractory non-infectious uveitis with ultra-widefield fundus fluorescein angiography. Int Ophthalmol 42, 2107–2116 (2022). https://doi.org/10.1007/s10792-021-02209-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10792-021-02209-x

Keywords

Search

Navigation